Debt Clock, Cash Situation Push Elan To Explore Options – Sale, Alliance, Merger?
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm engages Citgroup to explore strategic options, but some key stakeholders are not encouraged by the news
You may also be interested in...
Painting a Rosy Picture, Beleaguered Elan Seeks To Leave Its Troubles Behind
Elan reveals a hidden sweetener in its J&J deal, which will enable it to bid for the half of Tysabri it doesn't already own in the event Biogen is bought.
Painting a Rosy Picture, Beleaguered Elan Seeks To Leave Its Troubles Behind
Elan reveals a hidden sweetener in its J&J deal, which will enable it to bid for the half of Tysabri it doesn't already own in the event Biogen is bought.
J&J And Elan Strike A Deal On Key Alzheimer's Disease Assets
Six months after announcing it was looking at strategic alternatives, Elan's beleaguered management has found a way to address its challenges: It announced July 2 that it is selling its Alzheimer's immunotherapy program (AIP), which includes the high-profile Alzheimer's disease drug bapineuzumab and all related assets, to Johnson & Johnson for what essentially amounts to $500 million in the near-term and a commitment from J&J to buy an 18.4 percent stake in Elan for $1 billion